We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Leukemia Fusion Genes Screening Kit Gets CE IVD Status

By LabMedica International staff writers
Posted on 16 Jun 2015
Print article
Image: The Leukemia Fusion Genes (Q30) Screening Kit (Photo courtesy of QuanDx Inc.).
Image: The Leukemia Fusion Genes (Q30) Screening Kit (Photo courtesy of QuanDx Inc.).
The Leukemia Fusion Genes screening kit has been released as a Conformité Européenne In Vitro Diagnostic (CE-IVD) product under the European Directive for In Vitro Diagnostic Medical Devices.

The screening kit provides a sensitive, specific, reliable and cost-effective tool that is easy to perform for the routine screening of leukemia fusion transcripts. The ability to detect cancer specific fusion genes is important in clinical settings to ensure that correct diagnosis is made and the optimal treatment is chosen.

Leukemia Fusion Genes (Q30) Screening Kit (QuanDx Inc.; San Francisco, CA, USA) is a qualitative in vitro diagnostic device for use in a clinical laboratory for the simultaneous detection of 30 fusion genes utilizing a novel multiplex reverse transcription real-time polymerase chain reaction (PCR) system. Fusion and control gene transcripts are co-amplified in each reaction and identified by specific fluorescent probes. Leukemia Fusion Genes (Q30) will transform current testing to provide a more efficient and economical system for optimizing patient testing as current methodologies to detect such fusion genes all have distinct shortcomings. The results of the test are ready in two to three hours.

Matthew Lei, PhD, Chief Executive Officer of QuanDx Inc., said, “This marks another significant step for our company and compliments our ISO 13485: 2003 certification in March. We have implemented the internal quality and regulatory processes necessary to move from selling a research use only product to an in vitro diagnostic product. CE marking demonstrates our commitment to provide quality diagnostic products to the European market. This is our first in vitro diagnostic product. The release of our CE marked product line is expected to expand the use of our assays for the identification of fusion genes in hematologic malignancies.”

Graeme Duncan, Vice President of Sales and Marketing at QuanDx, commented: “The CE marked Leukemia Fusion Genes product will be available in the European market beginning June 2015. The CE mark assures laboratories and clinicians that they can rely on Leukemia Fusion Genes Screening Kits to provide accurate results in their assessment and classification of hematological malignancies. The CE-IVD status of this Leukemia Fusion Genes (Q30) Screening Kit allows us to continue to expedite our plans to enter the clinical market in Europe in what is a key area of growth outside the USA.”

Related Links:

QuanDx Inc. 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.